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The phenanthridine alkaloid lycobetaine (ungeremine, Figure 1)
has been isolated as a minor constituent from several plant species
of the Amaryllidaceae family (Owen et al, 1976; Ghosal et al,
1986; Lee et al, 1994). Lycobetaine has been reported to exhibit
growth inhibitory properties in vitro (Wang et al, 1987; Ghosal
et al, 1988) and to show significant cytotoxic activity against
Ehrlich ascites carcinoma, ascites hepatoma, the leukaemias
L1210 and P388, Lewis lung carcinoma and Yoshida ascites
sarcoma in mice or in rats after i.p. injection (Zhang et al, 1981). In
nude mice with gastric cancer, lycobetaine has been reported to
extend the survival time and to decrease the tumour size (Wu et al,
1988). However, the underlying mechanism of action has not been
elucidated yet. The present study addresses potential mechanisms
of action of lycobetaine. 
MATERIALS AND METHODS 
Materials 
Lycobetaine was obtained by oxidation of lycorine with selenium
dioxide (Ghosal et al, 1986; He and Weng, 1989). Lycorine was
isolated from bulbs of Sternbergia lutea (Amaryllidaceae)
(Evidente et al, 1984) and characterized by HPLC and 1H-NMR
spectroscopy in comparison with reference material kindly
provided by Dr B Xu, Shanghai Institute of Materia Medica,
Chinese Academy of Sciences, China. All chemicals used were of
research grade. 
Cell lines 
The large cell lung tumour xenograft LXFL 529L was established
in serial passage onto nude mice, NMRI genetic background
(Berger et al, 1992) from which a permanent cell line was devel-
oped. The cell lines LXFL 529L, HL60, U937, K562 and Molt4
were cultured at 37˚C (5% CO2 and 98% humidity) in RMPI 1640
medium with addition of 1% penicillin/streptomycin and 10% fetal
calf serum (FCS). Medium, FCS and penicillin/streptomycin were
obtained from Gibco Life Technologies (Karlsruhe, Germany).
Cells were subcultured twice weekly and were routinely tested for
the absence of mycoplasm contamination. 
Sulforhodamine B assay 
Growth inhibition was determined using the sulforhodamine B
assay (Skehan et al, 1990) with slight modifications as described
previously (Marko et al, 2001). 
Lycobetaine acts as a selective topoisomerase IIβ
poison and inhibits the growth of human tumour cells 
HU Barthelmes2, E Niederberger1, T Roth4, K Schulte1, WC Tang1, F Boege2, H-H Fiebig3,4, G Eisenbrand1 and
D Marko1
1Department of Chemistry, Division of Food Chemistry and Environmental Toxicology, University of Kaiserslautern, Erwin-Schroedinger Str. 52, 67663
Kaiserslautern; 2Medizinische Poliklinik, University of Würzburg Medical School, Klinikstr. 6–8, 97070 Würzburg; 3Tumor Biology Center at the University of
Freiburg, Breisacher Str. 117, 79106 Freiburg i. Br.; 4Institute for Experimental Oncology, Oncotest GmbH, Am Flughafen 8–10, 79110 Freiburg i. Br., Germany 
Summary The phenanthridine alkaloid lycobetaine is a minor constituent of Amaryllidaceae. Inhibition of cell growth was studied in the
clonogenic assay on 21 human tumour xenografts (mean IC50 = 0.8 µ M). The growth of human leukaemia cell lines was also potently inhibited
(mean IC50 = 1.3 µ M). Athymic nude mice, carrying s.c. implanted human gastric tumour xenograft GXF251, were treated i.p. with lycobetaine
for 4 weeks, resulting in a marked tumour growth delay. Lycobetaine was found to act as a specific topoisomerase IIβ poison. In the presence
of calf thymus DNA, pure recombinant human topoisomerase IIβ protein was selectively depleted from SDS-gels, whereas no depletion of
topoisomerase IIα protein was observed. In A431 cells immunoband-depletion of topoisomerase IIβ was induced, suggesting stabilization of
the covalent catalytic DNA-intermediate in living cells. It is reasonable to assume that this mechanism will cause or at least contribute
significantly to the antitumour activity. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: lycobetaine; ungeremine; topoisomerase IIβ ; cleavable complex; clonogenic assay; gastric carcinoma 
1585
Received 24 January 2001 
Revised 20 July 2001 
Accepted 24 August 2001 
Correspondence to: D Marko 
British Journal of Cancer (2001) 85(10), 1585–1591
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2142, available online at http://www.idealibrary.com on  http://www.bjcancer.com
OH
O
O
N
+
Figure 1 Structure of lycobetaine Clonogenic assay 
18 human tumours established in serial passage in nude mice (NMRI
nu/nu strain) and 3 cell line-derived xenografts were used (Berger
et al, 1992). The clonogenic assay was performed as a modified 2-
layer soft agar assay as described previously (Drees et al, 1997).
Inhibition of colony formation was expressed as treated/control ×
100 (T/C%). IC50 and IC70 values were determined by plotting
compound concentration versus cell viability. Mean IC50 and IC70
values were calculated as described previously (Roth et al, 1999). 
In vivo testing 
Fragments of the gastric cancer GXF251 were implanted subcuta-
neously in both flanks of female nude mice (NMRI nu/nu strain).
When tumours were approximately 3 × 3 mm, mice were
randomly assigned to treatment and control groups. Lycobetaine
was administered i.p. dissolved in 0.9% NaCl. Group 1 was treated
twice weekly for 4 weeks with 60 mg kg–1 bw. Body weight and
tumour diameters were measured twice weekly. Tumour volumes
were calculated from 2 perpendicular diameters measured by
calipers (a × b2/2) and the optimal T/C as well as the tumour
growth delay in days was determined (Drees et al, 1997). All tests
were performed according to UKCCCR Guidelines for the Welfare
of Animals in Experimental Neoplasia (Workman et al, 1998). 
Single cell gel electrophoresis (Comet assay) 
HL60 cells (1 × 106 ml–1) were incubated for 3 h in RPMI 1640
medium containing 10% FCS in the presence or absence of the
test compounds. Single cell gel electrophoresis (SCGE) was
performed according to the method of Gedik (Gedik et al, 1992).
DNA-strand breaks were detected by fluorescence microscopy and
quantified by using the comet assay II system (Perceptive instru-
ments, Suffolk, UK). 
Biochemical analysis of topoisomerase-directed 
drug-effects 
DNA-relaxation, and -cleavage we measured with pUC18-plasmid
as a DNA substrate, whereas DNA-decatenation activity was
measured with C. fasciculata catenated kinetoplast-DNA (obtained
from TopoGen Inc, Columbus, Ohio). Human topoisomerases I, IIα ,
and IIβ were expressed in S. cerevisiae and purified by various
chromatographic steps, as described by Knudsen et al, (1996).
Assay conditions and electrophoretic separation of the reaction
products were precisely described by Boege (1996). For the study
of topoisomerase-directed drug effects in cells, we used human
A431 epidermoid cells. Cell culture and immunoblotting of cellular
DNA-topoisomerases was done as described in Meyer et al (1997).
Gels were documented by digital photography. X-ray films were
digitalized with a flatbed scanner. Since statistical analysis could
not be applied to the data, we present examples of results represen-
tative of at least 3 experiments with similar outcome performed on
different days and with different sets of enzymes or cells. 
Flow cytometry 
LXFL529L cells were incubated for 72 h with compounds on
10 cm Petri-dishes in RPMI 1640 medium containing 10% FCS.
Flow cytometry was performed as described previously (Marko
et al, 1998). 
RESULTS 
Growth inhibition in vitro 
The activity profile in the clonogenic assay with human tumour
xenograft cells shows that lycobetaine inhibits the growth of the 21
tumour xenografts tested within a range of 2 nM up to 27.5 µ M,
with a mean IC70 value of 3.3 µ M (mean IC50 = 0.8 µ M, Figure 2).
Substantial activity (IC70 ≤ 1 µ M) was observed against the 2 gastric
carcinomas tested, the large-cell lung carcinoma LXFL529, the
small-cell lung carcinoma LXFS538, the colon carcinoma CXF280,
the ovarian carcinoma OVXF1023 and the pancreatic carcinoma
PAXF546. Marked growth inhibition (IC70 ≤ 3 µ M) was also
observed for 2 bladder carcinomas (BXF1299 and BXF1301), one
melanoma (MEXF989) and the renal carcinoma RXF944LX. The
mammary carcinomas (MX1, MCF7X) and the lung adenocarci-
nomas (LXFA289, LXFA526) appear to be more resistant to lyco-
betaine. This also applies to the other colorectal, ovarian,
pancreatic and renal tumours tested, as well as the second
melanoma, resulting in an overall heterogeneous response pattern
for these tumours. Human leukaemia cell lines were also growth
inhibited in the low micromolar range (mean IC50 = 1.3 µ M, SRB
assay), as shown in Table 1. Similar results were obtained for the
xenograft derived permanent human large-cell lung carcinoma cell
line LXFL529L, tested for comparison (Table 1). 
Antitumour efficacy in vivo 
The gastric tumour xenograft GXF251 was chosen for in vivo
testing. Athymic nude mice, carrying s.c. implanted tumour
xenografts, were treated i.p. twice weekly for 4 weeks (Table 2).
This group received a total dose of 480 mg kg–1, resulting in a
growth inhibition of about 50%. The schedule was well tolerated,
as judged by only marginal effects on body weight gain, however,
a late toxic death (day 21) was recorded (Table 2). 
Induction of DNA strand breaks 
HL 60 cells were incubated for 3 h with lycobetaine. DNA strand
breaks were determined using the comet assay (Gedik et al, 1992)
(Figure 3). The extent of DNA damage induced correlates with the
fluorescence intensity of the comets, quantified as tail intensity.
Incubation with lycobetaine for 3 h resulted in 32% slightly and
10% severely damaged cells at 5 µ M, whereas at 10 µ M 82%
slightly and 6% severely damaged cells were observed, with only
12% of the cells remaining intact. 
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Table 1 Effect of lycobetaine on the growth of human tumour cell lines 
Cell line Growth inhibitiona
IC50 (µ M) 
HL60 1.3 ± 0.5 
Molt 4 0.7 ± 0.4 
K 562 0.8 ± 0.03 
U 937 2.5 ± 0.1 
LXFL 529L 1.2 ± 0.1 
aGrowth inhibition of human tumour cell lines was determined using the
sulforhodamine B assay, incubation time 72 h. IC50 values were calculated as
survival of treated cells over control cells × 100 (T/C%). Values are given as
mean ± SD of 2–4 independent experiments, each done in quadruplicate. Lycobetaine stimulates DNA-cleavage by
topoisomerase IIβ but not -α
In view of the pronounced DNA damaging effect of lycobetaine in
the comet assay, we suspected that the drug might act as a stabi-
lizer of covalent DNA intermediates of topoisomerase I and/or II.
To test this hypothesis, we incubated pUC18 plasmid DNA with
pure recombinant human topoisomerases and various concentra-
tions of lycobetaine. Controls included camptothecin or VM-26 as
typical poisons of topoisomerase I or II, respectively. Reaction
products were electrophoresed in the presence of ethidium
bromide in order to resolve relaxed and supercoiled as well as
linearized and nicked plasmid forms. Figure 4A shows a typical
result obtained with topoisomerase I. Obviously the enzyme alone
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Figure 2 Activity profile of lycobetaine on the growth of human tumour xenografts in the clonogenic assay. Cell suspensions of human tumour xenografts,
grown onto nude mice, were seeded in soft agar and cultivated for 6–15 days, depending on the doubling time of the tumour stem cells. Lycobetaine was
applied continuously in various concentrations. After the incubation time and staining with a vital dye, tumour colonies with a diameter > 50 µ m were counted
with an automatic image analysis system. Variations of individual IC70s (drug concentration reducing colony formation to 30% of control values) from the mean
value are shown as bars in the logarithmically scaled axis. Bars to the left demonstrate IC70s lower than the mean value, bars to the right demonstrate higher
values 
Table 2 Tumour growth inhibition in vivoa
Group Animals/tumours  Dose  Schedule in  Toxic  Body weight   Optimal  Tumour  Tumour
per group (mg kg–1) days (i.p.) deaths change (%) on day T/C doubling time  growth delay 
14 21 28 
(days) (days)
Control 6/8 0 5 times/week  0 + 8 +5 +1 – 7.2 – 
for 4 weeks
Group 1 5/10 60 twice weekly  1 –1 –4 –11 50.6 9.4 2.1 
for 4 weeks (day 21)
aTreatment of nude mice bearing subcutaneously the human gastric tumour xenograft GXF251 started at a tumour size of approximately 80 mm3 (day 20 after
tumour implantation). Lycobetaine was dissolved in 0.9% NaCl and applicated by i.p. injection. Mice in the control group were treated with the vehicle (0.9% NaCl). (lane 2) relaxed the plasmid completely, whereas 50 µ M camp-
tothecin (lane 1) inhibited the relaxation reaction and at the same
time induced nicking of a considerable portion of the substrate.
These observations are in a perfect agreement with the known fact
that camptothecin promotes topoisomerase I-mediated DNA single-
stranded cleavage. When various concentrations of lycobetaine
ranging from 1–100 µ M (lanes 5–9) were tested in a similar
fashion, it became apparent that lycobetaine did not promote
plasmid nicking in the same way as did camptothecin. Thus, it can
be concluded that lycobetaine does not damage DNA via stimu-
lating topoisomerase I-mediated DNA cleavage. It should be noted
that lycobetaine shifted the closed circular plasmid in a dose-
dependent fashion. The shift was clearly also dependent on topoiso-
merase I. It was not seen with lycobetaine and DNA alone (lane 4),
but also appeared in coincubations of topoisomerase II and lyco-
betaine (Figure 4B, lanes 6–9). Since the reaction products were
thoroughly digested with proteinase before electrophoresis, the
apparent band shifts cannot be due to the binding of topoiso-
merases to the DNA. They could, however, reflect the introduction
of positive supercoils into the plasmid by topoisomerase I or II,
which might be driven by the DNA-intercalating properties of
lycobetaine, and, thus, be dependent on lycobetaine and topoiso-
merase. As that may be, the phenomenon was not further pursued,
because it seemed irrelevant with respect to the molecular basis of
the DNA-damaging properties of lycobetaine. 
Figure 4B shows typical results of DNA-cleavage experiments
with topoisomerase IIα (top) or -β (bottom). Most notably, lyco-
betaine clearly stimulated topoisomerase II-mediated DNA
double- stranded cleavage (indicated by plasmid-linearization).
However, it did so only in reactions containing the β -isoform and
not in reactions containing the α -isoenzyme (lanes 7–9, compare
top to bottom). The dose–response relationship of this effect was
bell shaped (maximum at 10–30 µ M), as to be expected from a
substance that has also DNA-intercalating properties. The
apparent selectivity of lycobetaine for the β -isoform of topoiso-
merase II was clearly opposed by the non-selective effect of the
classic topoisomerase II poison VM-26, which stimulated DNA-
cleavage of both isoenzymes (lanes 4 and 5). Taken together, these
results suggested that lycobetaine might be a β -selective topo-
isomerase II-poison. 
Lycobetaine stabilizes the DNA-linkage of
topoisomerase IIβ but not -α
To corroborate these findings, we approached the problem from the
protein side, studying depletion of topoisomerase II proteins from
SDS gels by drug-induced DNA-linkage. For this purpose we incu-
bated pure recombinant human topoisomerase IIα or -β with calf
thymus DNA in the presence or absence of drugs, stopped the reac-
tion with SDS, and subjected these samples to SDS-polyacrylamide
gel electrophoresis followed by Coomassie staining. Figure 5, lane 1
shows that 2 µ g topoisomerase IIα (top) or -β (bottom) alone were
readily detectable by the protein staining. The protein bands of both
isoenzymes were only marginally diminished upon incubation
with 6 µ g calf thymus DNA (Figure 5, lane 2), whereas coincuba-
tion with DNA and VP-16 (lane 3) or VM-26 (lane 4), which are
both established topoisomerase II poisons, effected a more or less
complete removal of the protein bands of both isoenzymes from the
gel, because the covalent enzyme–DNA complexes stabilized by
these drugs are too large to enter the gel. A similar extent of band-
depletion was also obtained with lycobetaine. However, in this
case only topoisomerase IIβ became depleted whereas the 
α -isoform was not affected (Figure 5, lanes 6 and 7, compare top to
bottom). Again, the lycobetaine effect on the DNA linkage of topo-
isomerase IIβ had a maximum between 10–30 µ M and decreased at
higher concentrations (Figure 5, lane 8). 
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Figure 3 Single-cell gel electrophoresis (comet assay). HL 60 cells were
treated for 3 h with lycobetaine. Subsequent lysis and single cell gel
electrophoresis were performed as described in Materials and methods. 
(A) Control. (B) Lycobetaine 10 µ M, 3 h. The categories of DNA damage
were separated according of the proportion of extranuclear fluorescence into
‘not damaged’ (proportion of the extranuclear fluorescence < 17%), slightly
damaged (extranuclear fluorescence 17–60%) and severely damaged (> 60%)
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Figure 4 Topoisomerase DNA-cleavage assays. 60 ng topoisomerase I (A)
or 300 ng topoisomerase IIα (B, top) or 300 ng topoisomerase IIβ (B, bottom)
were incubated with or without 200 ng pUC18 DNA at 37˚C. Camptothecin or
lycobetaine were added to the incubations as indicated. Reactions were
stopped after 30 min with 1% SDS. Samples were digested with proteinase
K, and subjected to submarine 1% agarose gelelectrophoresis in the
presence of ethidiumbromide. UV- transilluminated gels were documented by
digital photography. This is a representative result of 5 identical experiments
with similar outcome. Arrows in the bottom panel of (B) indicate linearization
of plasmid DNA promoted by a concerted action of topoisomerase IIβ and
lycobetaine Lycobetaine promotes selective immunoband-depletion
of topoisomerase IIβ in cells 
In summary, the data shown in Figures 4 and 5 strongly suggest
that lycobetaine might be a topoisomerase II poison selective for
the β -form of the enzyme. As a next step we investigated whether
it would also target topoisomerase IIβ in living cells. For this
purpose, we added lycobetaine to the cell culture medium of A431
cells and assessed subsequently by immunoblotting the cellular
pools of free topoisomerase IIα and -β that were not linked to
DNA as a consequence of drug exposure. Drug-induced DNA-
linkage of the cellular topoisomerase II can be determined as a loss
of the respective protein band, because the DNA-linked enzymes
are retained in the application slot together with the genomic
DNA. In the absence of drug (Figure 6A, lanes 1 and 11) topoiso-
merase IIα (top) and -β (bottom) were readily detectable in the
cells during the entire time-frame of the experiment. Upon expo-
sure to lycobetaine topoisomerase IIα was not at all affected,
whereas the signal of topoisomerase IIβ became clearly dimin-
ished (Figure 6A, lanes 6 and 9, compare bottom and top). The
disappearance of the topoisomerase IIβ could in principle be due
to proteolysis of the enzyme. However this is unlikely, because
typical proteolytic degradation products are not apparent on the
blot. Considering in addition the effect of the drug on purified
topoisomerase IIβ (Figures 4 and 5) it seems most likely that the
disappearance of the topoisomerase IIβ bands shown in Figure 6 is
due to the induction of DNA-linkage. Maximal depletions were
obtained with 200 µ M lycobetaine, whereas minor effects were
seen at higher concentrations (Figure 6A, bottom, compare lanes 6
and 7 or lanes 9 and 10). Most notably, the onset of these effects
seemed to be delayed by at least one hour (Figure 6A, bottom,
lanes 2–4) and increased gradually during incubations between 3
to 6 hours. Moreover, the effective concentration range seemed to
increase during prolonged incubation periods (Figure 6A, bottom,
compare lanes 5 with 8 and 7 with 10). Figure 6B compares the
kinetics of topoisomerase II band depletion by lycobetaine with
those of the classical poison VM-26. It is quite obvious, that the 2
drugs act on a different time-scale. The onset of VM-26 is more or
less instantaneous and maximal band depletion is already obtained
after 30 min (Figure 6B, lane 4), whereas lycobetaine needs as
long as 120 minutes to produce a similar effect (Figure 6B, lane 9).
Moreover, lycobetaine acts selectively on topoisomerase IIβ ,
whereas VM-26 depletes topoisomerase IIα and  β (Figure 6B,
compare top and bottom). 
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Figure 5 Protein band depletion of pure topoisomerase II. 2 µ g of pure
recombinant human topoisomerase IIα (top) or -β (bottom) were mixed with
6 µ g calf thymus DNA. Lycobetaine, VM-26, or VP-16 were added, as
indicated. The sample in lane 1 was without DNA. Samples were incubated
at 37˚C for 30 min. Incubations were stopped with 1% SDS. Samples were
then subjected to SDS-gel electrophoresis on 5.5% polyacrylamide gels.
Gels were stained with coomassie blue, transilluminated and documented by
digital photography. This is a representative result of 3 identical experiments
with similar outcome 
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Figure 6 Immunoband depletion of topoisomerase IIα and -β in A431-cells.
Lycobetaine or VM-26 was added at the concentrations indicated to the
medium of non-confluent monolayer cultures of 105 A431 cells and culture
was continued for the indicated periods of time. Subsequently the cells were
lysed with 1% hot SDS and the cell lysates were rapidly applied to SDS-gel
electrophoresis on 5.5% polyacrylamide gels, followed by Western blotting
and immunostaining with rabbit peptide antibodies specific for the
carboxyterminus of human topoisomerase IIα (top panels) or -β (bottom
panels). Controls (lanes 1 and 11 in (A) and lanes 1 and 12 in (B)) were
treated similarly without addition of drugs Cell cycle distribution 
A further prediction of this type of mechanism of action, would be a
block in the G2/M-phase of the cell cycle. To test that assumption,
LXFL529L cells were incubated for 72 h with lycobetaine. In
untreated cells, 11% of the cells were found in the G2/M phase. In the
presence of 5 µ M lycobetaine, a slight increase of cells in the G1/G0
phase became apparent, concomitant with a significant loss of cells
in S phase and a distinct increase of the G2/M cells (25%). The arrest
in G2/M was strongly enhanced upon incubation with 7.5 µ M lyco-
betaine (32%) and an increase of cells with reduced DNA staining
compared to cells in G1 was observed. In agreement with flow
cytometry results, at 10 µ M lycobetaine, cells showed a distinct
shrinkage of the cell volume and condensation of the chromatin,
features characteristic for apoptosis induction (data not shown). 
DISCUSSION 
Our results show that lycobetaine is a potent inhibitor of human
tumour cell growth in the colony forming and in the SRB assay. In
the clonogenic assay, enhanced activity against gastric carcinomas
was observed. Lycobetaine was also active on certain lung and
ovarian xenografts (Figure 2). This is in line with reports about
substantial activity of lycobetaine in clinical studies in the treat-
ment of ovarian and gastric carcinomas, at a dosage that was not
reported to lead to significant systemic toxicity (He and Weng,
1989). In mice bearing the gastric carcinoma GXF251, lycobetaine
exhibits substantial antitumour activity with minor toxicity on a
twice weekly schedule, implying tolerable weight loss and 1 late
toxic death (day 21). The antitumour efficacy was enhanced when
lycobetaine was applied daily (30 mg kg–1), resulting in a higher
total dose. This resulted in increased toxicity, as judged from body
weight loss, however, no toxic deaths were observed (data not
shown). For exploration of an optimal dosing schedule further
experiments appear warranted. 
Using fluorescence microscopy, we observed exclusive local-
ization of lycobetaine in the nucleus of human LXFL529L cells,
comparable to ethidium bromide and Hoechst H33258 (data not
shown). Lycobetaine has been described previously already as a
DNA intercalating agent with preference for G–C pairs (Wu et al,
1987; Liu et al, 1989; Gan et al, 1992; Chen et al, 1997). This is
consistent with our finding on its efficient competition for
ethidium bromide intercalation into calf thymus DNA (data not
shown). Furthermore, lycobetaine was found to compete effec-
tively with the minor groove-binding ligand Hoechst H33258
(data not shown). In the comet assay, intense DNA damage was
observed after treatment of HL60 cells with lycobetaine for 3 h
(Figure 3). Mechanistically, DNA damage might occur as a conse-
quence of the intercalative/minor groove-binding properties of
lycobetaine, or, alternatively, lycobetaine might target as well topoi-
somerases directly. Minor groove-binding ligands have been
reported to be potent topoisomerase I inhibitors with a mechanism
similar to camptothecin, which is trapping the DNA-topoisomerase
I cleavable complex (Chen et al, 1993). A number of DNA interca-
lators such as adriamycin, amsacrine or etoposide have already
been shown to represent potent topoisomerase II inhibitors (Davies
et al, 1988). We present here several lines of evidence characterizing
lycobetaine as a topoisomerase IIβ -selective poison. Firstly, it stimu-
lates DNA-cleavage by topoisomerase IIβ but not by topoisomerase
IIα (Figure 4). Secondly, in the presence of calf thymus DNA it
depletes pure recombinant human topoisomerase IIβ protein from
SDS-gels, whereas it does not deplete topoisomerase IIα protein
under similar conditions (Figure 5). Thirdly, it induces topoiso-
merase IIβ -selective immunoband-depletion in A431-cells (Figure
6). The latter result suggests that the drug does indeed stabilize the
covalent catalytic DNA-intermediate in living cells, although we
cannot altogether exclude that it induces proteolysis of the
enzyme. However, in the view of the data obtained with pure
topoisomerase IIβ (Figures 4 and 5) this is a less likely alternative.
It is reasonable to assume therefore that poisoning of topoisomerase
IIβ will cause or at least contribute significantly to the DNA-
damaging properties of lycobetaine that might be relevant for the
antitumour activity of the drug. As to be expected from a topoiso-
merase II inhibitor, lycobetaine was found to induce in a concentra-
tion-dependent fashion arrest of LXFL529L lung carcinoma cells in
the G2/M-phase of the cell cycle with indication for the onset of
apoptosis. 
Recently, an analogue of the herbicide Assure has been
described (XK 469, NSC 697887), representing a synthetic
quinoxaline phenoxypropionic acid derivative (Gao et al, 1999),
which was found to inhibit topoisomerase IIβ at mM concentra-
tions. On the basis of our data, lycobetaine is at least 10-fold more
potent than XK 469. Lycobetaine is rapidly taken up into cells and
locates to the nucleus. However, in view of the delay observed
for the full onset of topoisomerase IIβ inhibition, it cannot be
excluded at present that intracellular transport or metabolism plays
also a role. 
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